Increased Serum Cathepsin K in Patients with Coronary Artery Disease

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2014 Jun 24

PMID 24954318

Citations 13

Authors

Xiang Li

Yuzi Li

Jiyong Jin

Dehao Jin

Lan Cui

Xiangshan Li

Yanna Rei

Haiying Jiang

Guangxian Zhao

Guang Yang

Enbo Zhu

Yongshan Nan

Xianwu Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Cathepsin K is a potent collagenase implicated in human and animal atherosclerosis-based vascular remodeling. This study examined the hypothesis that serum CatK is associated with the prevalence of coronary artery disease (CAD).

Materials And Methods: Between January 2011 and December 2012, 256 consecutive subjects were enrolled from among patients who underwent coronary angiography and percutaneous coronary intervention treatment. A total of 129 age-matched subjects served as controls.

Results: The subjects' serum cathepsin K and high sensitive C-reactive protein (hs-CRP) and high-density lipoprotein cholesterol were measured. The patients with CAD had significantly higher serum cathepsin K levels compared to the controls (130.8±25.5 ng/mL vs. 86.9±25.5 ng/mL, p<0.001), and the patients with acute coronary syndrome had significantly higher serum cathepsin K levels compared to those with stable angina pectoris (137.1±26.9 ng/mL vs. 102.6±12.9 ng/mL, p<0.001). A linear regression analysis showed that overall, the cathepsin K levels were inversely correlated with the high-density lipoprotein levels (r=-0.29, p<0.01) and positively with hs-CRP levels (r=0.32, p<0.01). Multiple logistic regression analyses shows that cathepsin K levels were independent predictors of CAD (odds ratio, 1.76; 95% confidence interval, 1.12 to 1.56; p<0.01).

Conclusion: These data indicated that elevated levels of cathepsin K are closely associated with the presence of CAD and that circulating cathepsin K serves a useful biomarker for CAD.

Citing Articles

Pro-Osteogenic Effect of the Nutraceutical BlastiMin Complex in Women with Osteoporosis or Osteopenia: An Open Intervention Clinical Trial.

Sabatelli S, Scarpa E, Giuliani A, Giordani C, Sabbatinelli J, Rippo M Int J Mol Sci. 2024; 25(16).

PMID: 39201253 PMC: 11354786. DOI: 10.3390/ijms25168565.

Decreased Cathepsin-K Mirrors the Severity of Subclinical Atherosclerosis in Kidney Transplant Recipients.

Bolignano D, Greco M, Arcidiacono V, Presta P, Caglioti A, Russo E Rev Cardiovasc Med. 2024; 23(9):311.

PMID: 39077719 PMC: 11262360. DOI: 10.31083/j.rcm2309311.

Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives.

Mijanovic O, Jakovleva A, Brankovic A, Zdravkova K, Pualic M, Belozerskaya T Int J Mol Sci. 2022; 23(22).

PMID: 36430239 PMC: 9698382. DOI: 10.3390/ijms232213762.

Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.

Qian D, He L, Zhang Q, Li W, Tang D, Wu C Curr Oncol. 2022; 29(8):5963-5987.

PMID: 36005209 PMC: 9406569. DOI: 10.3390/curroncol29080471.

Association of Circulating Cathepsin S and Cardiovascular Disease Among Patients With Type 2 Diabetes: A Cross-Sectional Community-Based Study.

Jing Y, Shi J, Lu B, Zhang W, Yang Y, Wen J Front Endocrinol (Lausanne). 2021; 12:615913.

PMID: 33746900 PMC: 7973458. DOI: 10.3389/fendo.2021.615913.

References

Schwartz S, Galis Z, Rosenfeld M, Falk E . Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007; 27(4):705-13. DOI: 10.1161/01.ATV.0000261709.34878.20. View

Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Ehara S . Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2006; 97(2):175-80. DOI: 10.1016/j.amjcard.2005.08.020. View

Cheng X, Kuzuya M, Sasaki T, Arakawa K, Kanda S, Sumi D . Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol. 2003; 164(1):243-51. PMC: 1602234. DOI: 10.1016/S0002-9440(10)63114-8. View

Li X, Liu Z, Cheng Z, Cheng X . Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease. Chonnam Med J. 2012; 48(2):77-85. PMC: 3434795. DOI: 10.4068/cmj.2012.48.2.77. View

Li Z, Hou W, Bromme D . Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry. 2000; 39(3):529-36. DOI: 10.1021/bi992251u. View

Liu J, Ma L, Yang J, Ren A, Sun Z, Yan G . Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis. 2005; 186(2):411-9. DOI: 10.1016/j.atherosclerosis.2005.08.001. View

Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y . Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation. 2006; 113(16):1993-2001. DOI: 10.1161/CIRCULATIONAHA.105.596031. View

Shi G, Sukhova G, Grubb A, Ducharme A, Rhode L, Lee R . Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999; 104(9):1191-7. PMC: 409823. DOI: 10.1172/JCI7709. View

Reiser J, Adair B, Reinheckel T . Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010; 120(10):3421-31. PMC: 2947230. DOI: 10.1172/JCI42918. View

10.

Geluk C, Post W, Hillege H, Tio R, Tijssen J, van Dijk R . C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis. 2006; 196(1):372-382. DOI: 10.1016/j.atherosclerosis.2006.11.013. View

11.

Smith E, Tomlinson L, Ford M, McMahon L, Rajkumar C, Holt S . Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension. 2012; 59(5):973-8. DOI: 10.1161/HYPERTENSIONAHA.111.187807. View

12.

Libby P, Ridker P, Maseri A . Inflammation and atherosclerosis. Circulation. 2002; 105(9):1135-43. DOI: 10.1161/hc0902.104353. View

13.

Cheng X, Shi G, Kuzuya M, Sasaki T, Okumura K, Murohara T . Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation. 2012; 125(12):1551-62. DOI: 10.1161/CIRCULATIONAHA.111.066712. View

14.

Libby P, Lichtman A, Hansson G . Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013; 38(6):1092-104. PMC: 3764500. DOI: 10.1016/j.immuni.2013.06.009. View

15.

Liu Y, Li X, Peng D, Tan Z, Liu H, Qing Y . Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol. 2009; 103(4):476-81. PMC: 2752663. DOI: 10.1016/j.amjcard.2008.10.011. View

16.

Liu J, Sukhova G, Yang J, Sun J, Ma L, Ren A . Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2005; 184(2):302-11. DOI: 10.1016/j.atherosclerosis.2005.05.012. View

17.

Cheng X, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E . Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension. 2006; 48(5):979-87. DOI: 10.1161/01.HYP.0000242331.99369.2f. View

18.

Sun J, Sukhova G, Zhang J, Chen H, Sjoberg S, Libby P . Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2011; 32(1):15-23. PMC: 3230668. DOI: 10.1161/ATVBAHA.111.235002. View

19.

Turk V, Turk B, Turk D . Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001; 20(17):4629-33. PMC: 125585. DOI: 10.1093/emboj/20.17.4629. View

20.

Burns-Kurtis C, Olzinski A, Needle S, Fox J, Capper E, Kelly F . Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit. Cardiovasc Res. 2004; 62(3):610-20. DOI: 10.1016/j.cardiores.2004.02.002. View